Rare and Orphan Disease Therapeutics Bi-Weekly Industry Events & M&A Update — September 14–28, 2026

Read the report

SlidesScroll

1 of 7

←→Full screen

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › RARE AND ORPHAN DISEASE THERAPEUTICS

Pipeline Names Take the Markdown While a Commercial Buyer Steps Forward

This update covers rare and orphan disease therapeutics from September 14–28, 2026: the period's movers, the company news behind them, and the one transaction the companies themselves announced.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Rare and Orphan Disease Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

Sources & methodology

1

← Previous

1 / 7 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › RARE AND ORPHAN DISEASE THERAPEUTICS

Next →

What each page shows

The analyst’s walkthrough of the deck, page by page.

1. 01
   BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

   HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › RARE AND ORPHAN DISEASE THERAPEUTICS

   Cover slide introducing the bi-weekly rare and orphan disease therapeutics industry events and M&A update for September 14–28, 2026.

   This bi-weekly update covers rare and orphan disease therapeutics from September 14–28, 2026: what changed, who moved and why, what transacted, and what it means. We built it to move straight into the evidence, starting with the market's biggest moves and ending with what they change for you.

   Everything on this page

   BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › RARE AND ORPHAN DISEASE THERAPEUTICS Pipeline Names Take the Markdown While a Commercial Buyer Steps Forward This update covers rare and orphan disease therapeutics from September 14–28, 2026: the period's movers, the company news behind them, and the one transaction the companies themselves announced. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Rare and Orphan Disease Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

2. 02
   THE BI-WEEKLY BOTTOM LINE

   Programme News Got Priced Hard While a Commercial Owner Kept Buying

   This page summarizes the two-week period's market moves and the one completed transaction across the 39 covered names.

   Twenty-eight of the 39 covered names fell over the period, with a -5.0% median move against a +0.8% gain for the S&P 500, so the pressure sat inside the sector rather than the broader market. The deepest declines were concentrated in programme-stage names, while PTC Therapeutics completed its acquisition of the ST-920 Fabry gene therapy — the period's only company-announced transaction. That split between repriced pipelines and an active commercial buyer is the throughline for the rest of this update. So what: two forces, programme risk and commercial-stage buying power, are moving in opposite directions right now.

   Everything on this page

   THE BI-WEEKLY BOTTOM LINE Programme News Got Priced Hard While a Commercial Owner Kept Buying The two-week period in one page · 39 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Rare and Orphan Disease Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 28 of 39 Covered Names Fell; The Median Move Was -5.0% The S&P 500 returned +0.8% over the same two-week period, so the pressure sat inside the sector rather than across the market. Eleven covered names still finished higher. 2 Programme-Stage Names Carried the Period's Deepest Markdowns Sionna Therapeutics, Inc. (SION) finished -38.0%, Crescent Biopharma, Inc. (CBIO) -26.2%, Wave Life Sciences Ltd. (WVE) -19.9% and Pharvaris N.V. (PHVS) -17.9%. SION's worst single session was -17.0% on Sep 18; CBIO's was -13.7% on Sep 23. 3 One Agreed Transaction Landed: PTC Closed on a Fabry Gene Therapy PTC Therapeutics, Inc. (PTCT) completed its acquisition of the ST-920 Fabry disease gene therapy on Sep 21. It is the period's only company-announced transaction in the set, and it came from a commercial-stage rare-disease owner rather than a development-stage platform. 4 The Standing Split Between Pipelines and Commercial Franchises Held NeuraCap's standing view prices this sector on CY2027E EV / Revenue, with a 4.7x sector median and a 19.8x Premium-tier median against 1.7x at the Discount tier. This period's evidence — programme-stage drawdowns alongside a commercial buyer closing a purchase — is consistent with that split rather than a challenge to it. +12.0% Best mover — Gyre Therapeutics, Inc. (GYRE) worst: SION -38.0% · 11 up / 28 down of 39 covered -5.0% Sector median two-week return vs S&P 500 +0.8% 1 Transaction agreed in the two-week period from company announcements; not yet in the precedent record 1 Company filings in the window 8-K events read for driver attribution

3. 03
   PUBLIC MARKET MOVERS

   Programme Updates, Not the Market, Set the Price This Period

   This page ranks the period's largest close-to-close price moves against the sector median and market benchmark.

   Programme updates, not the broader market, set the price this period, with a sector median of -5.0% against a materiality bar of 9.6% (sector-relative) used to flag the moves worth explaining. The S&P 500 returned +0.8% over the same window, underscoring that the sector's pressure was specific rather than market-wide. Each move on this page is linked back to the filing or headline recorded in the window, and where no driver is recorded, the page says so. So what: reading the movers next to their disclosed catalysts tells you which names are being repriced on evidence versus sentiment.

   Everything on this page

   PUBLIC MARKET MOVERS Programme Updates, Not the Market, Set the Price This Period Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -5.0% · S&P 500 +0.8% · materiality bar ±9.6% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Rare and Orphan Disease Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -5.0% Sionna Therapeutics, Inc. (SION) -38.0% Shares moved following Sionna's Sep 14 plan to advance the SION-451 plus SION-2222 dual combination into a Phase 2a proof-of-concept trial, supported by post hoc sweat chloride analyses; investor-alert notices followed from Sep 15. Combination plans in cystic fibrosis get judged on the strength of the underlying evidence, not on the trial design alone. COMPANY-SPECIFIC Crescent Biopharma, Inc. (CBIO) -26.2% No notable in-window news was identified that clearly explains the move. At -26.2%, the decline ran well below the -5.0% median for covered names. Premium-tier valuations leave the least room for error when the covered set is heading lower. UNEXPLAINED Wave Life Sciences Ltd. (WVE) -19.9% Shares moved following the Sep 23 announcement that Wave initiated a Phase 2a combination trial of WVE-007 with tirzepatide in obesity — the same session as the -9.2% single-day move. A new chief business officer was named Sep 22. A platform pointed at a large indication can dilute the rare-disease premium investors were paying for. COMPANY-SPECIFIC Gyre Therapeutics, Inc. (GYRE) +12.0% No notable in-window news was identified that clearly explains the move. At +12.0%, Gyre Therapeutics, Inc. (GYRE) finished well above the -5.0% median for covered names, with a +7.2% session on Sep 17. Core-tier commercial names traded to their own rhythm while programme-stage peers repriced. UNEXPLAINED

4. 04
   MAJOR NEWS & INDUSTRY CATALYSTS

   A Clinical Hold, a Litigation Calendar, and a Label Expansion Cut Loose

   This page lists the two-week period's highest-impact company news events with links to their source filings.

   This period's highest-impact events include a clinical hold, a litigation calendar, and a label expansion decision, each linked to its underlying filing or article. The 'why it matters' lines are NeuraCap's read of the recorded evidence, not the companies' own statements. Sources follow a fixed reliability order — SEC filings first, then press releases and established outlets — so every claim traces back to something a reader can open. So what: this page gives you the catalyst calendar behind the price moves on the previous page.

   Everything on this page

   MAJOR NEWS & INDUSTRY CATALYSTS A Clinical Hold, a Litigation Calendar, and a Label Expansion Cut Loose The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Rare and Orphan Disease Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 15 · NEWS · GlobeNewsWire Aardvark faces a securities class action over ARD-101 safety statements before the Phase 3 pause The complaint concerns safety representations that preceded a Phase 3 pause and a full FDA clinical hold on ARD-101. Lead-asset concentration converts a single regulatory setback into a whole-company diligence question. Sep 14 · NEWS · Newsfile Corp Law firm reminds Aardvark investors of the October 13, 2026 lead plaintiff deadline The litigation calendar now sits alongside the clinical calendar at Aardvark Therapeutics, Inc. Common Stock. That combination tends to shape the timing and leverage of any financing or partnering conversation. Runway decisions get harder when a company is managing a legal timetable and a regulatory one together. Sep 15 · 8-K · SEC EDGAR BioMarin discontinues VOXZOGO development in children with Noonan syndrome BioMarin Pharmaceutical Inc. (BMRN) cited feasibility and the current treatment landscape, not safety or efficacy. Franchise value stays anchored to the indications a company already treats when expansion economics do not clear. Sep 15 · NEWS · PRNewsWire Investors in Aardvark notified of a pending securities fraud class action Multiple firms circulated notices in the same few days, which keeps the ARD-101 clinical hold in front of the market. Sustained attention on a single disclosure raises the evidentiary bar for the company's next update. The market is treating regulatory status changes in orphan programmes as the key credibility test. Sep 15 · NEWS · GlobeNewsWire Investor rights firm flags the October 13, 2026 deadline in the Aardvark action The repeated notices mark how much of the period's sector news flow came from one company's regulatory setback rather than from operating progress. That imbalance is part of why the covered set finished lower. When news flow is dominated by setbacks, operating progress elsewhere gets less credit than usual. Sep 15 · NEWS · GlobeNewsWire Shareholder rights firm opens lead plaintiff process in the Aardvark securities action For the sector, the signal is procedural rather than scientific: the ARD-101 hold now has a formal legal track. Counterparties assessing the asset will want the regulatory correspondence before anything else. Regulatory correspondence quality is doing more work in diligence than the headline data set.

5. 05
   M&A & STRATEGIC ACTIVITY

   A Commercial Rare-Disease Owner Adds a Fabry Gene Therapy

   This page covers the period's one agreed transaction and the broader precedent-transaction record.

   PTC Therapeutics completed its acquisition of the ST-920 Fabry disease gene therapy on September 21 — the period's only company-announced transaction, and it came from a commercial-stage rare-disease owner. This deal sits against a broader precedent set of recorded rare-disease transactions, giving it context against past dealmaking in the space. Deal multiples shown are LTM at announcement where disclosed, and the 'why the deal happened' read is NeuraCap's own. So what: a commercial owner adding a gene therapy asset while pipeline names get marked down is the clearest signal in this update.

   Everything on this page

   M&A & STRATEGIC ACTIVITY A Commercial Rare-Disease Owner Adds a Fabry Gene Therapy September 14–28, 2026 · 1 agreed by company announcement · precedent transactions: 40 recorded deals Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Rare and Orphan Disease Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 AGREED IN THE PERIOD — FROM COMPANY ANNOUNCEMENTS Sep 21 · PTC Therapeutics, Inc. (PTCT) PTC Therapeutics, Inc. (PTCT) completes its acquisition of ST-920, a gene therapy for Fabry disease A commercial rare-disease owner adding a gene-targeted asset in a genetically defined indication. The read is appetite for assets that can plug into an existing patient-services hub and established payer relationships. Terms and multiples enter the precedent record once the filing is processed; the reference set alongside is unchanged. 40 Recorded precedent transactions the reference set buyers and sellers price against

6. 06
   WHAT IT MEANS

   What the Period Changes for Operators, Buyers and Advisers

   This page translates the period's evidence into implications for operators, acquirers and advisers.

   For owners and operators, this period's moves tracked programme and regulatory news rather than commercial execution, a reminder that the operating engine remains the differentiator. For acquirers, PTC's completed ST-920 purchase adds a current reference point for gene-targeted rare-disease assets bought by a commercial owner. For advisers, the storyline is easy to carry into a board room: pipeline names were broadly repriced while a commercial buyer kept acting. So what: these are observations from the recorded evidence, not recommendations, and they frame how each audience should read the next two weeks.

   Everything on this page

   WHAT IT MEANS What the Period Changes for Operators, Buyers and Advisers The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Rare and Orphan Disease Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 4.7x 38 companies in the study 3 valuation tiers Standing thesis: Rare and Orphan Disease Therapeutics Split Between Pipelines and Orphan Commercialization FOR OWNERS & OPERATORS The Moves Tracked Programme News; The Operating Engine Is Still the Differentiator Companies in the space traded on trial plans and regulatory status this period, not on commercial execution. FOR ACQUIRERS One Completed Purchase, and a Wider Gap Between Programme Risk and Commercial Franchises PTC's completion of the ST-920 Fabry acquisition adds a current reference point for gene-targeted rare assets bought by a commercial owner; the record now carries 40 trailing transactions. FOR ADVISORS Lead with the Split: Programme-Stage Repricing Against Commercial Buyers Acting The period's evidence is specific and easy to carry into a board room: 28 of 39 covered names fell with a -5.0% median, the deepest moves followed programme and regulatory news, BioMarin discontinued a Noonan syndrome expansion on feasibility grounds

7. 07
   SOURCES & METHODOLOGY

   Sources, Methodology and Important Notice

   This page explains the sources, methodology and limitations behind every figure in the update.

   Every figure in this update links back to the record it was taken from, and the publishers and filings drawn on for the period are listed on this page. This is how we keep the calibrated language throughout the deck grounded in verifiable sources rather than assumption. So what: use this page as the audit trail whenever a figure or read needs to be checked against its source.

   Everything on this page

   SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Rare and Orphan Disease Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 1 name below the floor was excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T183036Z_560_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: globenewswire.com · newsfilecorp.com · sec.gov · prnewswire.com

More coverage in Health Care

• Sector Report · Sep 28, 2026Rare and Orphan Disease Therapeutics Sector Outlook — September 2026
• Sector Report · Sep 28, 2026Medical Imaging Equipment Sector Outlook — September 2026
• Bi-Weekly Update · Sep 28, 2026Neurology and CNS Therapeutics Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
• Bi-Weekly Update · Sep 28, 2026Medical Imaging Equipment Bi-Weekly Industry Events & M&A Update — September 14–28, 2026